A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.

Key facts

Study ID

NCT05026866

Run by

Eli Lilly and Company

People needed

2996

Starts

2021-08-27

Expected to finish

2027-11-01

Last updated by the study team

2026-01-21

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.
• Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
• Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
• Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
• Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.
• Treatment Extension: (Study Period II Placebo Group Only)
• Are actively participating in Study AACM at the conclusion of Study Period III.

You may not qualify if…

• Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.
• Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years.
• History of cancer with high risk of recurrence and preventing completion of the trial.
• History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).
• Have any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.
• Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.
• Have a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), >4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.
• Have had prior treatment with a passive anti-amyloid immunotherapy <5 half-lives prior to randomization.
• Have received active immunization against amyloid beta (Aβ) in any other study.
• Have received active immunization against Aβ in any other study.
• Current or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.
• Addendum 7 Exclusion Criteria:
• Same as the main study except contraindications for florbetapir F 18 PET are exclusionary.

Where it is running

• Alabama Psychiatry - Birmingham - Brookwood Medical Center Drive — Homewood, Alabama, United States
• Rehabilitation & Neurological Services — Huntsville, Alabama, United States
• Care Access - 801 South Power Road, Mesa — Mesa, Arizona, United States
• Banner Alzheimer's Institute — Phoenix, Arizona, United States
• Banner Alzheimer's Institute Tucson — Tucson, Arizona, United States
• Center for Neurosciences — Tucson, Arizona, United States
• Care Access - Berkeley — Berkeley, California, United States
• Care Access - Beverly Hills — Beverly Hills, California, United States
• Velocity Clinical Research, Chula Vista — Chula Vista, California, United States
• Valley Clinical Trials, Inc. — Covina, California, United States
• Neurology Center of North Orange County — Fullerton, California, United States
• Care Access - Gilroy — Gilroy, California, United States
• Marvel Clinical Research — Huntington Beach, California, United States
• Care Access Research - Huntington Beach — Huntington Beach, California, United States
• Irvine Clinical Research — Irvine, California, United States
• Option Care - Irvine — Irvine, California, United States
• Kaizen Brain Center — La Jolla, California, United States
• Velocity Clinical Research, San Diego — La Mesa, California, United States
• Pacific Research Network — Lemon Grove, California, United States
• Healthy Brain Clinic — Long Beach, California, United States
• Neurovations — Napa, California, United States
• Care Access - Newport Beach — Newport Beach, California, United States
• Valley Clinical Trials, Inc. — Northridge, California, United States
• Inland Psychiatric Medical Group — Redlands, California, United States
• Parkway Medical Center — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.